Drug Discovery

The recent publication of a comprehensive human proteome atlas in the journal Nature represents a transformative shift in biological research, moving the focus from static genetic code to the dynamic world of functional proteins. By quantifying over 13,600 proteins across a diverse range of

The medical community has long grappled with the reality that even the most promising biomarkers in oncology do not guarantee a successful outcome for every individual patient diagnosed with metastatic disease. In the realm of colorectal cancer, the identification of deficient DNA mismatch repair

The global pharmaceutical landscape is currently navigating a profound transformation as researchers attempt to reconcile the astronomical promises of artificial intelligence with the uncompromising demands of laboratory validation. While the allure of accelerated data analysis remains a powerful

The relentless progression of advanced clear cell renal cell carcinoma often leaves clinicians and patients with few viable options after standard therapies have been exhausted. This specific form of kidney cancer is notorious for its ability to develop resistance to established treatments,

The persistent challenge of managing generalized myasthenia gravis has long forced patients to rely on treatments that merely suppress symptoms rather than addressing the underlying immune dysfunction that causes debilitating muscle weakness. Kyverna Therapeutics and ElevateBio have recently

Ivan Kairatov is a seasoned expert in biopharmaceutical research and development, possessing a profound understanding of the technological shifts currently reshaping oncology. With a career dedicated to navigating the complexities of drug innovation, he has a unique perspective on how precision